Trial Profile
A Prospective, Efficacy Study of NuCel in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Cervical Spine
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Amniotic cell therapy-NuCel (Primary)
- Indications Intervertebral disc degeneration; Spinal stenosis; Spondylosis
- Focus Therapeutic Use
- Sponsors Nutech Medical
- 19 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 19 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
- 19 Dec 2016 Status changed from active, no longer recruiting to discontinued.